I was awarded my PhD in Nanosciences, from the University of Barcelona (Spain) in 2021, under the supervision of Prof. Dr. Samuel Sanchez and Dr. Tania Patino at the Institute of Bioengineering of Catalonia. My PhD work was focused in developing nanotherapeutic strategies using nanorobotics, having developed nanobots capable of boosting anticancer delivery, enhancing cell targeting, and shrinking bladder tumors by a striking 90% in vivo. During this time, I acquired a wide range of skills in nanofabrication and characterization, single-particle and swarm analysis of several kinds of nanorobots, as well as different skills in cellular biology. I was also fortunate to develop some of my work at the Max Planck Institute for Intelligent Systems (Germany), and forge important collaborations that allowed my research to grow.
Throughout my career, I had the privilege of working not only in reputable research centers but also in pharmaceutical companies, such as Aptar and Sanofi, participating in several multidisciplinary projects, ranging from molecular biology, chemistry, physics and computational sciences.
I have devoted my career to advancing drug delivery technologies through nanomaterials synthesis, surface engineering, and assessing their efficacy using advanced in vitro, in vivo and ex vivo models. My multidisciplinary background, together with my passion for nanomedicine drives me to takle challenges in different biomedical scenarios, ranging from cancer to cardiovascular diseases.
Thus, I have recently joined the Translational Bionanomicro Theragenerative Medicine Group led by Professor Hélder A. Santos, at the Department of Biomaterials and Biomedical Technology at UMCG. As a MSCA-IF postdoctoral fellow, with the project MyoNanoCell, I aim to develop a disruptively new platform for heart fibrosis therapy and cardiac regeneration. Despite the widespread prevalence and consequences of cardiac fibrosis, current benchmark therapies still remain lacking efficacy, and novel therapies still present severe limitations. Thus, there is an urgent unmed need for new efficient therapies. By combining cardiomyogenic delivery with the ability to modulate the cardiac microenvironment and recognize cardiac fibroblasts, MyoNanoCell aims to directly impact contractility and heart function. This project involves the design and fabrication of enzyme-powered nanohybrids, assisted by microfluidics, which will carry cardiomyogentic molecules and modulate the cardiac microenvironment whilst delivering them. The use of micro and nano fabrication techniques, as well as molecular and cell biology is crucial for the success of this project.
You can know more details about my MSCA project in the link below:
https://cordis.europa.eu/project/id/10114
